Navigation Links
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
Date:5/19/2008

ies Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated future financial results and product development. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (ii) risks related to achieving positive clinical trial results; (iii) the results of the InterMune CAPACITY trials of pirfenidone may differ materially from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone in Japan; (iv) the designation of pirfenidone for Fast Track status by the FDA does not guarantee that the FDA will grant Priority Review of the NDA filed by InterMune in connection with the approval of pirfenidone for the treatment of IPF in the United States. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Progress on Pirfenidone in IPF
2. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Announces Start of Phase 1b Trial of ITMN-191
5. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
6. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
7. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
8. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
9. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
10. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
11. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... NORWALK, Conn. , July 23, 2014 ... NeurologyTimes.com – a new online community and information ... them better manage and treat their patients with ... conditions, coupled with an aging population, necessitates greater access ... specific disorders.  Key statistics on neurological conditions include: ...
(Date:7/23/2014)... , July 23, 2014 Pharmavite LLC announced ... chief customer officer effective immediately. Toll recently served as ... and marketing, category management, private label and sales administration ... his new global role, Toll will expand his responsibilities ... planning. "Toll,s appointment to chief customer officer ...
(Date:7/23/2014)... DUBLIN , July 23, 2014 ... addition of the "Global Electrophysiology Ablation Catheters ... http://photos.prnewswire.com/prnh/20130307/600769 ... to remove or destroy faulty electrical pathways from ... rhythms (also known as cardiac arrhythmias). Cardiac arrhythmias ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3
... , , MOUNTAIN VIEW, Calif., Dec. 29 ... developing innovative, next-generation medical therapies to address unmet needs in ... Drug Application (NDA) has been submitted to the U.S. Food ... drug for the treatment of obesity, including weight loss and ...
... , , REDWOOD CITY, Calif., Dec. 28 Codexis, ... Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The shares of common stock to be sold in ... certain of its stockholders. , Credit Suisse Securities (USA) LLC and ...
Cached Medicine Technology:VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 2VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 4VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 5Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering 2
(Date:7/23/2014)... CA (PRWEB) July 23, 2014 “Unlike ... will focus on developing your own unique gifts, talents ... techniques and clichéd sales verbiage, “says Ja Marr Brown. ... Your Sales Story?" which chronicles Brown’s transformation from nearly ... Person of The Year, winning every sales contest offered ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The puffiness ... diminished using non-surgical techniques, according to a new guide ... eyes serum sold in the U.S. is now available ... . , The complimentary guide that is now published ... struggle with under eye puffiness. While surgical techniques are ...
(Date:7/23/2014)... Edmond, Oklahoma (PRWEB) July 23, 2014 ... North America’s leading provider of in-home care for ... Healthy Longevity Webinar Series featuring experts in a ... upcoming webinar will feature licensed clinical social worker ... the most common causes of caregiver stress and ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, 2014 ... been exposed to some form of childhood trauma than their ... seems to apply solely to military men, not women. ... cause for concern, given that early childhood exposure to various ... population has been linked to a higher adult risk for ...
(Date:7/23/2014)... if a suspicious skin lesion is painful or itchy ... to be cancerous, according to a new study headed ... Dermatology at Temple University School of Medicine. , The ... July 23, 2014, found that nearly 36. 9 percent ... 28.2 percent involve pain. Non-melanoma skin cancers specifically, ...
Breaking Medicine News(10 mins):Health News:Using Your Story and Not Technique to Achieve Sales Success 2Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 3Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 2Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 3Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
... Farm, South Africa, concluded that male circumcision could considerably ... the researchers studied the economical aspects of this approach ... new research is published in PLoS Medicine, and suggests ... in South Africa, mainly through savings on the cost ...
... that Health Care Workers (HCWs) in developing countries are particularly ... latent infection with tuberculosis, which is active. The infected ... ,One third of the world's population is ... most people, the bug causes no health problems and it ...
... a heart surgery years ago underwent the same procedure ... he is raring to get back to work after recuperating ... blood vessel called aorta, in his heart ,that was torn. ... surgical procedure for a condition called dissecting aortic aneurysm.As a ...
... study based on research in pregnant mice suggest that ... cruciferous vegetables during pregnancy// may show more resistance to ... in their adulthood. ,In this study, researchers ... discovered that a phytochemical administered in pregnant mice, help ...
... receive transfusions during heart bypass surgery have a higher ... their operation. ,In fact, this increased risk ... bypass patients are more likely than men to die ... more likely to receive blood during heart bypass operations, ...
... today welcomed the first formal agreement to deliver a ... the move as a win for patients and doctors ... the first organisation to sign up to deliver the ... rebates immediately after paying the doctor’s bill. ...
Cached Medicine News:Health News:Pioneer Heart Surgeon Faced the Scalpel at 98 2Health News:Pregnant Women- Eat Broccoli And Cabbage 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 3
... VALTRAC™ Single Use Biofragmentable Anastomosis Rings., ... end-to-side and side-to-side anastomosis., ,VALTRAC™ ... multiple intestinal anastomoses but not for ... may be used in any disease ...
... use instrument to create an automatic ... ,The PURSTRING™ 45 disposable instrument has ... and cardiac surgery for temporary and ... PURSTRING™ 65 disposable instrument has application ...
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
The Auto Suture™ EEA™ reusable stainless steel sizer set has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
Medicine Products: